B-098 Clinical comparison of five assays for the detection of anti-dsdna antibodies and their correlation with complement consumption

Abstract

Abstract Background Anti-dsDNA antibodies are highly specific and part of the classification criteria for systemic lupus erythematosus (SLE). They correlate with disease activity and contribute to the pathogenesis of lupus nephritis (LN). This study aimed to compare five methods for anti-dsDNA antibody detection and to estimate their association with complement consumption. Methods 186 samples were collected at Labcorp and tested on five assays: Crithidia luciliae indirect immunofluorescence test (CLIFT, Euroimmun, Lübeck Germany), BioPlex 2200 dsDNA (BioRad, Hercules, US), QUANTA Lite HA dsDNA ELISA, QUANTA Flash dsDNA chemiluminescent immunoassay (CIA), and Aptiva dsDNA, a particle-based multi-analyte technology (PMAT) immunoassay (all 3 assays, Inova Diagnostics, USA). Complement C3 and C4, measured with Cobas c 502 (Roche Diagnostics, USA), were used as serological surrogates and compared to each assay to assess the correlation with disease activity. Results The quantitative agreement varied between 0.60 (BioPlex vs. CLIFT) and 0.96 (Aptiva vs. QUANTA Flash) (Table 1). The C3 agreement from highest to lowest was: HA dsDNA ELISA, CLIFT, QUANTA Flash, Aptiva, then BioPlex 2200. The findings were compared to qualitative results derived from CLIFT testing, since CLIFT is often used as the confirmation assay for anti-dsDNA. The highest area under the curve (AUC) from the receiver operating characteristic (ROC) curve was found for QUANTA Flash (0.95) followed by Aptiva and HA ELISA (both 0.94) and then BioPlex (0.87). Conclusions Anti-dsDNA antibodies measured using different methods showed varying agreement with CLIFT and complement consumption. Aptiva and QUANTA Flash dsDNA were highly correlated and in strong concordance with low C3 levels.